Skip to main content
Premium Trial:

Request an Annual Quote

Orchid s Revenues and Loss Up in Q1; Company to Genotype Irish Sheep

NEW YORK, May 6 (GenomeWeb News) - Orchid BioSciences reported increased revenues and widening losses for the first quarter of 2004 today.


Revenues for the quarter totaled $13.5 million, up from $12.7 million during the first quarter of 2003.


R&D costs declined to $0.5 million, from $1.1 million for the year-ago period.


The company's net loss, which includes losses from Orchid's diagnostics unit, which it sold to Tepnel Life Sciences in January, was $8.1 million, or $.41 per share, up from $5 million, or $.45 per share, during the same quarter last year.


As of March 31, Orchid had $31.7 million in cash and cash equivalents and $1 million in restricted cash. This includes $28.1 million the company raised in an equity financing in February and by selling its diagnostics unit.


Separately, Orchid said today that its Cellmark unit will provide genotyping services for the National Genotyping Programme of the government of Ireland to help breed sheep with reduced susceptibility to scrapie.


Cellmark, which is part of Orchid BioSciences Europe, will make its genotyping services available to the 45,000 flock owners of Ireland.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.